Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies
Year: 2019
Type: conference-abstract
Source: Blood
Authors: John N. Allan, Krish Patel, Anthony R. Mato, William G. Wierda, Javier Pinilla Ibarz, Michael Y. Choi, Susan M. O'Brien, Jeff P. Sharman, Mazyar Shadman, Douglas E Gladstone, Matthew S. Davids, John M. Pagel, Renee Ward, Gary Acton, Pietro Taverna, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Institutions: Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, University of California San Diego, Moores Cancer Center, University of California, Irvine, University of California, Irvine Medical Center, UC Irvine Chao Family Comprehensive Cancer Center, Willamette Valley Cancer Institute and Research Center, Fred Hutch Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, Sunesis (United States)
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2983711926